D. Boral Capital Reaffirms Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)

D. Boral Capital reissued their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

A number of other analysts have also recently weighed in on HOTH. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a report on Monday, November 4th. Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price objective on shares of Hoth Therapeutics in a research report on Friday, October 11th.

Hoth Therapeutics Stock Performance

NASDAQ:HOTH opened at $1.90 on Tuesday. The company has a market capitalization of $13.12 million, a price-to-earnings ratio of -1.44 and a beta of 0.75. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80. The stock has a 50-day simple moving average of $0.88 and a 200 day simple moving average of $0.86.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.01). On average, equities research analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC acquired a new stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.